- Home
- ZLAB
ZLAB
Zai Lab Limited
as 12-17-2024 4:00pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 3.0B | IPO Year: | 2017 |
| Target Price: | $52.50 | AVG Volume (30 days): | 960.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.48 - $36.60 | Next Earning Date: | 11-12-2024 |
| Revenue: | $355,748,000 | Revenue Growth: | 35.01% |
| Revenue Growth (this year): | 48.5% | Revenue Growth (next year): | 47.37% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chen Yajing | ZLAB | Chief Financial Officer | Nov 1 '24 | Sell | $30.66 | 167 | $5,120.55 | 15,494 | |
| Chen Yajing | ZLAB | Chief Financial Officer | Oct 1 '24 | Sell | $25.40 | 301 | $7,644.80 | 15,494 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Zai Lab Announces Participation in Investor Conference in January 2025
TipRanks
15 days ago
Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
MT Newswires
16 days ago
Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint
Benzinga
16 days ago
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
MT Newswires
16 days ago
Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint
Business Wire
16 days ago
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Business Wire
20 days ago
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Simply Wall St.
22 days ago
Exploring Three High Growth Tech Stocks in the United States
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.